Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine in Untreated B-CLL Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Flow cytometry confirmed B-CLL~* No prior chemotherapy or immunotherapy~* Performance status 0-2~* Age \> 18 years old~* If childbearing age, woman you must be willing to use birth control for length of hydroxychloroquine use~* Must have capacity to consent for study and sign consent form~* Asymptomatic CLL not requiring treatment at time of study entry~Exclusion Criteria:~* Pregnancy~* Significant optic nerve pathology as documented by an opthalmologic exam~* Hypersensitivity to 4-aminoquinoline compound~* Patients taking cardiac glycosides and cyclosporine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine 400 mg po daily for up to one year.

Based on this trial design, predict the completion outcome and termination type (if applicable).